Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world:: A case-control study
Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world:: A case-control study
复制标题
DOI：
10.1089/apc.2005.19.421
复制
发表时间：
2005-07-01
影响因子：
4.9
通讯作者：
Orozco, C
中科院分区：
文献类型：
--
作者：
Padilla, S;Gutiérrez, F;Orozco, C
人们担心 HIV 感染患者使用替诺福韦 (TDF) 会产生肾毒性风险。我们进行了一项回顾性病例对照研究，包括 122 名连续未接受过 TDF 且开始接受含 TDF 方案治疗的患者和 194 名接受其他抗逆转录病毒药物抗逆转录病毒治疗的患者。在 12 个月的观察期内，TDF 组有 5 名患者 (4.1%) 出现 1 级或更高血清肌酐升高，而对照组有 1 名患者 (0.5%) 出现 1 级或更高血清肌酐升高 (p = 0.018)。只有 2 名 (1.6%) 患者因血清肌酐水平升高而停止 TDF 治疗。 5 名发生肌酐升高的患者中，有 4 名患者联合使用了 TDF 和洛匹那韦-利托那韦。在 12 个月的临床实践中使用 TDF 与轻度肾功能衰竭的低风险相关。需要进一步研究来评估该药物的长期肾脏安全性。
Concern exists about the risk of nephrotoxicity using tenofovir (TDF) in HIV-infected patients. We performed a retrospective case-control study including 122 consecutive TDF-naive patients who started treatment with TDF-containing regimens and 194 patients receiving antiretroviral therapy with other antiretroviral drugs. During a 12-month observation period 5 (4.1%) patients in the TDF group versus 1 (0.5%) in the control group developed grade 1 or higher serum creatinine elevations (p = 0.018). Only 2 (1.6%) patients discontinued TDF treatment as a result of serum creatinine level elevations. In 4 of the 5 patients developing creatinine elevations TDF was combined with lopinavir-ritonavir. The use of TDF in clinical practice during a 12-month period is associated with low risk of mild renal failure. Further studies to assess long-term renal safety of this drug are needed.